MedTrace Logo

Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine

NCT02987868 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-02-08

Study results available
· View outcomes & findings →

Summary

In a recent randomized, double-blind, cross-over clinical trial, serum growth hormone (hGH) increased 682% above baseline 120 minutes after oral administration of an amino acid-based dietary supplement (SeroVital), p=0.01 vs placebo. In contrast to the mechanism of hGH stimulation by ghrelin, the investigators hypothesize that the supplement suppresses somatostatin, a know inhibitor of both hGH and TSH. To test this hypothesis, the investigators measured triiodothyronine (T3) after administration of the amino acid-base supplement.

Conditions

  • Growth Hormone Treatment
  • Aging

Interventions

DRUG

Amino acid supplement first day

An orally administered supplement of the proprietary amino acid derivative

DRUG

Placebo first day

A non-active orally administered supplement of the proprietary amino acid derivative

DRUG

Amino acid supplement second day

An orally administered supplement of the proprietary amino acid derivative

DRUG

Placebo second day

A non-active orally administered supplement of the proprietary amino acid derivative

Sponsors & Collaborators

  • Pennington Biomedical Research Center

    lead OTHER

Principal Investigators

  • Frank Greenway, M.D. · Pennington Biomedical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2011-12-31
Completion
2012-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02987868 on ClinicalTrials.gov